Resalis Therapeutics presented preclinical and translational data at TIDES Europe showing an antisense oligonucleotide (ASO) targeting miR-22 that the company says drives durable, metabolically healthy weight loss in models. CSO Riccardo Panella argued the ASO approach targets fat metabolism and adipogenesis rather than appetite suppression, positioning it as an alternative to GLP-1 agonists. Resalis’ data emphasize tissue effects, preservation of muscle and bone, and potential broader metabolic benefits. The company is advancing its ASO program toward clinical development while highlighting mechanistic differentiation from peptide-based obesity drugs.